Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Prices $5.7B Senior Notes Offering

NEW YORK – Thermo Fisher Scientific today priced an underwritten offering of a series of euro- and dollar-denominated senior notes, in an aggregate principal amount of $5.7 billion.

The firm priced €800 million ($877.8 million) aggregate principal amount of its 0.125 percent senior notes due 2025; €800 million aggregate principal amount of its 0.5 percent senior notes due 2028; €900 million aggregate principal amount of its 0.875 percent senior notes due 2031; €900 million aggregate principal amount of its 1.5 percent senior notes due 2039; €1.0 billion aggregate principal amount of its 1.875 percent senior notes due 2049; and $900 million aggregate principal amount of its 2.6 percent senior notes due 2029.

Waltham, Massachusetts-based Thermo Fisher will use the funds to redeem two classes of senior notes with a total aggregate principal of $1.1 billion, as announced earlier this month.

Thermo Fisher will also use the funds to redeem $4.5 billion aggregate principal amount of outstanding senior notes issued by the firm or its subsidiaries, including all outstanding 6 percent senior notes due 2020 and 5 percent senior notes due 2021 issued by its Life Technologies subsidiary.

The joint book-running managers for the euro offering are Goldman Sachs, Merrill Lynch International, Citigroup Global Markets and JP Morgan. The joint book-running managers for the dollar-denominated offering are Goldman Sachs, Bank of America Securities, Credit Suisse Securities, and HSBC Securities.

The euro offering is expected to close on or about Sept. 30, and the dollar-denominated offering is expected to close on or about Oct. 8. The euro notes will pay interest on an annual basis, while the dollar-denominated notes will pay interest on a semi-annual basis.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.